‘The Words Will Pass with the Blowing Wind’: Staff and Parent Views of the Deferred Consent Process, with Prior Assent, Used in an Emergency Fluids Trial in Two African Hospitals

Sassy Molyneux1,2,3*, Maureen Njue1, Mwanamvua Boga4, Lilian Akello9, Peter Olupot-Olupot7, Charles Engoru8, Sarah Kiguli6, Kathryn Maitland4,5

1 Health Systems and Social Science Research Group, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya, 2 Centre for Tropical Medicine, University of Oxford, Oxford, United Kingdom, 3 The Ethox Centre, Department of Public Health and Primary Health Care, Oxford University, Oxford, United Kingdom, 4 Kilifi Clinical Trials Facility, Kenya Medical Research Institute-Wellcome Trust Research Programme, Kilifi, Kenya, 5 Wellcome Trust Centre for Clinical Tropical Medicine, Department of Paediatrics, Faculty of Medicine, Imperial College, London, United Kingdom, 6 Department of Paediatrics, Mulago National Referral Hospital, Makerere University, Kampala, Uganda, 7 Malaria Consortium, Kampala, Uganda

Abstract

Objective: To document and explore the views and experiences of key stakeholders regarding the consent procedures of an emergency research clinical trial examining immediate fluid resuscitation strategies, and to discuss the implications for similar trials in future.

Methods: A social science sub-study of the FEAST (Fluid Expansion As Supportive Therapy) trial. Interviews were held with trial team members (n = 30), health workers (n = 15) and parents (n = 51) from two purposively selected hospitals in Soroti, Uganda, and Kilifi, Kenya.

Findings: Overall, deferred consent with prior assent was seen by staff and parents as having the potential to protect the interests of both patients and researchers, and to avoid delays in starting treatment. An important challenge is that the validity of verbal assent is undermined when inadequate initial information is poorly understood. This concern needs to be balanced against the possibility that full prior consent on admission potentially causes harm through introducing delays. Full prior consent also potentially imposes worries on parents that clinicians are uncertain about how to proceed and that clinicians want to absolve themselves of any responsibility for the child’s outcome (some parents’ interpretation of the need for signed consent). Voluntariness is clearly compromised for both verbal assent and full prior consent in a context of such vulnerability and stress. Further challenges in obtaining verbal assent were: what to do in the absence of the household decision-maker (often the father); and how medical staff handle parents not giving a clear agreement or refusal.

Conclusion: While the challenges identified are faced in all research in low-income settings, they are magnified for emergency trials by the urgency of decision making and treatment needs. Consent options will need to be tailored to particular studies and settings, and might best be informed by consultation with staff members and community representatives using a deliberative approach.

Introduction

Alternatives to Full Prior Consent in Emergency Research

Emergency research involves people with a life-threatening medical condition that requires urgent intervention, and emergency trials are important to allow relevant interventions to be evaluated. Given that most interventions used in the treatment and management of critically ill children have at best only been tested in animals or in adults, there is a need for emergency paediatric trials to advance evidence-based paediatric practice, and child health and well-being [1].

In emergency paediatric research, prior consent by parents or other legal guardians is recommended by the EU, but is recognised as challenging given the urgency of the patient’s condition, and the difficulty for the guardian of assimilating trial information in such distressing circumstances [1,2]. Current
regulations in some European countries and in the United States allow for alternatives to full prior individual consent in emergency research, while guidelines elsewhere in the world vary or are not specifically addressed [3]. The FDA allows for alternatives to full prior individual consent only in specific situations, as follows [4]:

- The subject has a life-threatening condition that necessitates urgent intervention;
- Available treatments are unproven or satisfactory;
- Consent from the subject (or a surrogate) is not feasible due to the urgency of the subject’s condition;
- The research could not otherwise be performed;
- The risks and benefits are reasonable;
- There is a prospect that the trial will be of direct medical benefit to the patient/subject; and
- There is consultation with the community from which subjects will be drawn, including public disclosure of the study design and risks prior to commencement.

These conditions have been argued to be unnecessarily restrictive, and to have contributed to a decline in the amount of emergency research.

A range of alternatives to full prior individual consent have been suggested, with deferred consent distinguished here from retrospective consent through including prior consent. Assent refers to an affirmative agreement; an agreement which implies at least a minimal level of understanding and ability to indicate a choice (Table 1; drawing on [1,5,6,7]). Each alternative option has its limitations. While there is no consensus on the most appropriate approach, it is generally agreed that full information must be given to surrogates as soon as possible, and that guidelines and regulations that apply to all clinical studies must be adhered to [8,9], including having a Data Safety and Monitoring Board. Ideally, emergency research should also be reviewed by committees with special training [1,10].

Given the challenges in obtaining full prior consent in paediatric emergency research, and variability and controversy in current guidelines and regulations [3], documentation and exploration of alternative approaches to obtaining informed consent in emergency research involving children is needed. We therefore conducted a social science sub-study alongside an emergency paediatric care trial to document and explore the views and experiences of key stakeholders – trial team members, health workers and parents - regarding the consent procedures.

The Consent Process in the FEAST Trial

The FEAST (Fluid Expansion As Supportive Therapy) trial was an emergency paediatric trial aimed at identifying the best strategies for treating and managing critically sick children on admission to hospital with severe febrile illness and shock. The trial was conducted in six hospitals in three East African countries (Uganda, Tanzania and Kenya), and involved 3170 critically ill children – with an estimated mortality rate of 15% - aged between 2 months and 12 years. The trial was a 3-arm randomised open comparative trial of fluid resuscitation strategies with children randomised into: (1) Immediate volume resuscitation with normal (0.9%) saline; (2) immediate volume expansion with 5% human albumin solution (HAS); or (3) control: no immediate volume expansion. The trial has been described in detail elsewhere [11].

The trial team and colleagues drew upon existing guidance and commentaries to develop a consent process which included written prior consent where possible, but an option for deferred consent with prior assent for a sub-set of children who needed immediate resuscitation (where prior consent was not possible), or where guardians or parents were not available or were perceived to be so distressed they were unable to receive or understand information (Table 2).

In the FEAST trial, therefore, deferred consent involved a verbal assent from parents or guardians prior to enrolment (see Table 3 for information included) and a delayed full informed written consent after the child had stabilised and when it was perceived that parents were better able to receive, evaluate and discuss the information. The intention was that verbal assent allowed parents to make a decision about trial participation on the basis of brief information, and gave them an opportunity to ‘opt out’. For the children who died shortly after verbal assent on admission, and before full consent, parents were not approached for retrospective informed consent. As elsewhere [2,12,13], obtaining consent from bereaved parents was considered to potentially further distress parents at a profoundly emotional

---

**Table 1. Alternatives to prior individual consent in emergency paediatric research.**

| Type of consent          | Characteristics                                                                 | Critique                                                                                           |
|--------------------------|--------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Deferred consent         | Initial assent to enter the study is obtained. | Consent cannot be obtained after the intervention has already been given; consent is only therefore permission to remain in the study |
|                          | Full informed consent is deferred (delayed) until the patient has stabilised and/or surrogates are able to listen and understand trial information. Surrogates can withdraw at any point. |                                                                                                   |
| Proxy consent by third parties | An appropriate person other than the parent/immediate guardian who gives consent for the participant. Potential proxies include - legal representatives, and independent physicians. | Difficulties in ensuring independence of proxies. Proxies not capable of knowing the wishes of a parent especially without prior discussion. |
| Advanced consent/ Presumed consent | Potential participants are identified prior to meeting eligibility criteria and consent for future enrolment should they become eligible. | Difficult to identify participants in advance in emergency research. Potentially causes unnecessary distress or harm, especially where inclusion criteria are met. |
| Retrospective consent    | Initial research intervention occurs without the surrogate's consent. Consent takes place after the initiation or completion of the research intervention. | Participants have no control over what has been done in the past. |
| Waiver of consent        | Research intervention occurs without the participant’s or surrogate’s consent. | Considered to be a violation of patient autonomy.                                |

---

[10.1371/journal.pone.0054894.t001]
time, possibly resulting in parents blaming themselves for permitting research participation [3].

An intensive training and retraining process was conducted for the FEAST trial by trained facilitators, including specific modules on assent and consent. Interactive training methods drew upon trainees’ knowledge and experience to contribute ideas for handling potential field scenarios, within an institutionally agreed consent SOP [14]. The time required for verbal assent was generally 2–5 minutes and could be obtained at the bedside, even whilst other aspects of emergency care were being administered (e.g. airway, oxygen, hypoglycemia correction). Consent required the full attention of the parent or guardian and generally took 20–30 minutes depending upon the amount of discussion. The latest international guidelines [15] recommend rapid and prompt fluid resuscitation of shock within 15 minutes of diagnosis, and the WHO guidelines recommend treatment ‘as quickly as possible’ [16], illustrating the importance of the deferred consent option for some parents (Table 2). Consent processes were reviewed regularly by monitors, and staff were encouraged to raise any challenges in day to day trial administration to their line managers or to the trainers throughout the trial. As part of community engagement, trial specific information was shared with key communities before the trial began, with key communities defined as ward parents, and hospital ward staff and managers. Widespread information giving in communities was opted against given the large size of hospital catchment areas, the small proportion of children who would ultimately be eligible for the trial, and the potential for complex information given in large community meetings to cause unnecessary concerns about attending hospitals for care.

In this paper we present the findings of the social science sub-study of the FEAST trial, and consider the implications for similar trials in such settings in future. We do not seek to evaluate or discuss the ethics of the trial, which was approved by science and ethics committees in four countries (UK, Uganda, Kenya, and Tanzania).

Table 2. Criteria for deferred consent in FEAST Study [3].

| Degree of Emergency                                                                 | Consent Status                  |
|-------------------------------------------------------------------------------------|---------------------------------|
| Pre-terminal                                                                         | Deferred consent                |
| Immediate resuscitation: other life threatening complications e.g. seizures, hypoglycaemia, hypoxia | Deferred consent                |
| No other life threatening complications: parents able to receive and understand information | Full informed consent prior to enrolment |
| No other life threatening complications: Guardian or parent not available or; parent or guardian unable to receive or understand information | Deferred consent                |

do:10.1371/journal.pone.0054894.t002

Table 3. Phrasing of assent in the deferred consent process [3].

We are going to provide the treatment for your child that is recommended by the government.

We want to find out if we can improve on these current recommendations by trying new treatments that we think will work better. We do this by research.

All research is checked by independent committees to make sure that the potential benefits to individuals outweigh the risks. All participation in research is voluntary, and so you can refuse.

We would like your child to participate in research for us to learn the best way to give fluids to very sick children.

Do you agree for your child to take part in this research? You can say no and your child will still receive the same level of care with the governments recommended treatment.

Table 3. Phrasing of assent in the deferred consent process [3].

|                                             |                                             |
|---------------------------------------------|---------------------------------------------|
| We are going to provide the treatment for your child that is recommended by the government. |                                             |
| We want to find out if we can improve on these current recommendations by trying new treatments that we think will work better. We do this by research. |                                             |
| All research is checked by independent committees to make sure that the potential benefits to individuals outweigh the risks. All participation in research is voluntary, and so you can refuse. |                                             |
| We would like your child to participate in research for us to learn the best way to give fluids to very sick children. |                                             |
| Do you agree for your child to take part in this research? You can say no and your child will still receive the same level of care with the governments recommended treatment. |                                             |

do:10.1371/journal.pone.0054894.t003

Methods

Study Sites – two FEAST Trial Hospitals

The consent study was conducted in two FEAST trial sites: Kilifi District Hospital (KDH), Kenya and Soroti Regional Referral Hospital (SRRH), Uganda. The sites were purposively selected to offer differing experiences based on different background situations, levels and types of trial inputs into the site (Table 4), and therefore perceived individual benefits.

Consent Sub Study Data Collection and Analysis

We held interviews with parents and trial staff and health workers between June and December 2010, before the trial was stopped early in January 2011 by the Independent Data and Safety Monitoring committee because of lack of benefit and potential harm from bolus fluid in African hospitals compared to control [11].

Interviews with parents. 34 in-depth interviews were held with parents of participating children (15 in Kilifi; 19 in Soroti); and five with parents who had refused (all in Kilifi). In addition, we interviewed 12 parents of children concurrently admitted in the wards but not involved with the trial in Soroti. The equivalent figure for Kilifi was 138; a higher figure because these interviews were being conducted as part of a broader study. Trial participants were identified from trial data, and other parents on discharge from the wards. Inclusion of non-study parents was aimed at identifying whether issues raised by trial participant parents were more about high dependency ward experiences than the trial itself. Parents of children who had died were not included due to the very sensitive nature of such interviews. Interviews with parents were conducted in parents’ preferred language, by trained staff.

Interviews with trial staff and health workers. We interviewed 30 staff involved with the FEAST trial (15 in Soroti and 9 in Kilifi) individually, and held two group discussions with health workers (primarily nurses) in Kilifi (N = 15). Six additional individual interviews were held with hospital staff and managers. All staff interviews were conducted in English by SM and MN.
Rates and Types of Consent in the Study Sites

Information on consent rates and type was collected as part of the trial procedures (Table 5).

| Site                          | Kilifi District Hospital (KDH), Kenya | Soroti Regional Referral Hospital (SRRH), Uganda |
|-------------------------------|--------------------------------------|--------------------------------------------------|
| Size of paediatric wards     | 42 beds                              | 62 beds                                          |
| Experience conducting trials | Clinical trials conducted for over 20 years | First major research activity                      |
| Community engagement activities | Coordinated community engagement activities focusing on the institution and (where appropriate) specific studies | No formalised community engagement strategies for research |
| Employment and training of staff | Most staff within pre-existing clinical research group | Most staff involved in the trial trained and recruited specifically |
| Refusal rates for trial      | High relative to other sites         | Low relative particularly to KDH                  |
| Hospital user charges and other costs (a) | National exemption of charges for under five year olds, but little policy adherence. Food is provided for patients and most basic consumables available at a cost. | National exemption of charges for all admissions, but little policy adherence. Relates provide and cook food in hospital grounds, and purchase many consumables needed (e.g. gloves, intravenous lines, some medicines) from local shops. |
| Trial inputs into study site | Established clinical programme as a robust platform for clinical trials (b). Also, trial provided extra personnel for emergency triage and patient monitoring, additional diagnostic tests and service-wide training in emergency care. | Basic maintenance and painting of paediatric wards, emergency and triage equipment and training for all staff, and employment of additional personnel. |
| Trial benefits for individuals (d) | Close observation, treatment of new illnesses identified during admission, and free treatment of minor illnesses post discharge up clinical trial pack (c). | As with KDH, every trial participant was allocated a dedicated until the 28-day follow-up visit. |

(a) See [32,33] for information on lack of adherence to user fee policies.
(b) Includes substantial support to the hospital for medical personnel (doctors, clinical officers, nurses and ward assistants); paediatric drugs, devices and equipment. Research funds also support the construction and running of an 8-bed paediatric high dependency ward available to all paediatric admissions, regardless of research involvement.
(c) Including cannulae, syringes, infusion sets, antibiotics, anti-malarials and blood testing consumables. Not needed in KDH where such support is provided to all inpatients in HDU.
(d) The usual hospital admission fees for the participants were not waived during the trial, in an effort to ensure that parents did not feel obliged to join the trial to save money. However, in Soroti only a few patients in a semi-private room are charged fees by the hospital.

do:10.1371/journal.pone.0054894.t004

Across all six trial sites, 49% of parents gave full prior consent and 47% assent prior to randomisation as part of a deferred consent process. A small proportion (4%) only gave assent, with these patients dying before deferred consent could be sought. Only a tiny fraction (0.4%) of parents who initially assented or consented to participation in the trial later withdrew their children.

The number of children enrolled in the trial was higher in Soroti (n = 633; contributing 20% of total trial participants) than Kilifi (n = 216; contributing 6.8%). We found substantial and statistically significant differences between Kilifi and Soroti in rates of consent and in the proportion with prior assent. 87% of participants’ parents in Kilifi gave prior full consent (189/216); whereas in Soroti the equivalent proportion was 40% (257/633) (chi-squared p<0.0001). Just over half of parents in Soroti (54%) and 11% in Kilifi (p<0.0001) went through the prior assent with deferred consent. In Kilifi, a far higher proportion of screened and eligible participants refused consent (36%; 123/339) compared to Soroti (4%; 27/660) (p<0.0001).

Ethics Statement

The consent sub-study of the FEAST trial was approved by National Ethics Review committees in Kenya and Uganda (the Kenya Medical Research Institute Ethics Review Committee and the Makerere University Faculty of Medical Research and Ethics Committee respectively). Written consent was sought from all respondents. Interviews were conducted independently of the trial, led by researchers with a long interest in consent processes in East Africa [18,19,20]. All recordings, transcriptions and quotes have been anonymised to protect confidentiality.

Findings

Following an overview of the consent rates and types across the two sites, we present staff and then parent perceptions of the consent process, followed by two factors influencing perceptions: parental understanding and decision-making in the trial, and factors influencing this.

Rates and Types of Consent in the Study Sites

All interviews were recorded, transcribed, and - where relevant - translated. Data were analysed using a modified framework approach [17]. Data were imported into NVIVO 9, and organised using a coding tree developed by SM and MN based on pre-study areas of interest and independent reviews of a sub-set of transcriptions. Charts by theme allowed comparison of issues identified by site and type of interviewee.
standard of care, and therefore some information and an ability to opt out for parents was required:

I think we should [assent] because this is not standard treatment that you are giving; you are doing research and you don’t know for sure whether what you are giving is good or whether it’s bad…(Soroti\Staff\ST011).

Most staff involved in administering a deferred consent process with verbal assent were administering this form of consent for the first time and viewed it very positively. They appreciated that it allowed emergency treatments to be started without delay:

I felt that the hastened bit of it [referring to assent] was quite appropriate… because when the patient is that sick you also feel for the patient and you feel for that mother. (You think) ‘What if something happens before I start these fluids while maybe I am talking to this mother?’ (Kilifi\Staff\ST011).

Also regularly mentioned by staff was that including an option for verbal assent allowed them to continue with the research in a way that protected them from any later blame from parents for having enrolled children:

There are people who are really difficult. When you start doing something on the child and the child dies, then there you will be stuck: somebody can start saying that had it not been because of these [study procedures], my child would not have died…. (Soroti\Staff\ST012).

We have to tell them whatever is happening because if you don’t tell them and something happens, the blame will be on us (Kilifi\Staff\KL005).

Deferred consent (following initial verbal assent) was also described as ensuring that another formal step to support parents’ understanding and their ability to withdraw was introduced:

You know even you if you are in a state of shock (laughing) you may say yes to something if you are not mentally stable… you may say yes then later you say no when you came to that part of filling in the consent form… at that point it will be wise for you to withdraw that child from the study and it’s really understandable… it is very important to go back as soon as possible (Soroti\Staff\ST009).

A final argument often raised in favour of deferred consent was that it can allow some ‘buying of time’ to wait for key decision makers to arrive when children are brought to hospital by relatives other than their parents, or by a mother who does not want to make a definitive decision on her husbands’ behalf:

...depending on families there are mothers who can make decisions by themselves so those ones can accept, but there are these ones who rely on the father as the one to make decisions - majority of them go for the assent (Soroti\Staff\ST012).

This latter point was challenged by some interviewees, particularly in Kilifi, where there was some lack of clarity on whether or not there was a study-specific ‘arrangement’ to allow research to proceed in these circumstances. Some Kilifi-based interviewees were concerned that this would not be permitted in ethical practice more globally, and about how the child’s parents might later react if they heard their child had been assented by somebody else:

When it comes to relatives assenting or consenting for patients who are not their children it’s a bit tricky and because this child is not theirs… you never know how the parents will react, so I think an assent cannot...[be] for somebody who is not present (Kilifi\Staff\KL011).

Challenges and concerns shared by staff. The main challenge raised by staff was the validity of either assent or full consent when given by guardians during admission of a critically sick child:

Remember you are getting somebody in a very desperate situation and you are saying, okay I have screened this patient, and this patient is eligible now we have such and such a trial but at this stage I just need you to tell me whether you are willing or not willing to participate. Now to somebody who is desperate I think a yes answer is bigger than a no answer… the desperation here is not … to enter the trial but somebody is desperate to save the life of a very critically sick person (Soroti\Staff\MB001).

The above quote hints at parents feeling like they have to agree to ensure their children receive all emergency treatment rather than the study intervention. Other challenges highlighted by staff were parents not being able to listen given their anxiety, and – overlapping with both perceived pressure to agree and with difficulties in concentrating and understanding the information – parents believing that by agreeing to trial enrolment that all children would receive a fluid bolus (as opposed to no-bolus, the
control). The bolus was reportedly seen as primarily to benefit their child.

A potential risk regarding deferred consent raised more often in Soroti than in Kilifi was that the option could be overused; introducing ‘a laziness’ in staff. In Kilifi, some staff argued that assent could ultimately lead to more late refusals, with parents having less interest in continuing to be in the study and withdrawing permission once their child had begun to improve (the point at which full consent is sought). This was difficult to explore quantitatively, given the small numbers with deferred consent in Kilifi.

In both settings staff reported that even the assent process introduces delays through encouraging questions, which introduces a dilemma in delaying initiation of treatment. Apparently unclear among staff was exactly what information they should give during assent. Although SOPs include the information, and this was covered during training, some staff reported that what to say was ‘really much more left to the prerogative of the clinician or the nurse’. Some staff were also unclear about whether or not an actual ‘yes’ was required; reportedly a major challenge in both settings where mothers often told staff to ‘just do what you want’:

These mothers come with all their anxiety, the child is sick. As much as someone would try to look brave and to say that I have actually understood go ahead - … mostly they say ‘do what you can, what I want to see is my child well’ (Kilifi/Staff/KL011).

The challenge was whether to accept such comments as a form of implicit agreement. Also unclear to staff was how to handle mothers who want to wait for a father to decide on study participation. In both settings fathers are often the main decision-makers in households but may not be present when the child is admitted. The dilemma is whether or not the mother is using the husband as a way to politely refuse; as a form of ‘silent refusal’:

It’s quite hard because often the reason you are given is that maybe ‘huyu ni mto wa wenyewe’ [this is the owner’s - i.e. the father’s - child]…., ‘I need the father also to give consent’ or that ‘I am waiting for the father’. So often they will not really come out and tell you that it is KEMRI [that is worrying me] but they always give other reasons (Kilifi/Staff/KL009).

One Kilifi staff member described asking the mother if she herself felt comfortable with the trial, and if so, suggesting that the child was enrolled and that the husband be fully informed on arrival. Because when fathers do later come, they ‘are usually not problematic so it’s just the fear the mothers have but the fathers are usually quite positive, quite ok to accept’. However some parents’ comments illustrate the potentially serious consequences of going against a father’s wishes:

you don’t know how they are living at their home……..that [ie a woman deciding in the absence of a husband] may cause her to be slapped (laughs)… because the husband may want to know why she has done that; why she didn’t wait for her husband to come…. That may cause chaos (Kilifi/Parent/KLF 004).

The provision in the FEAST trial to waiver full consent if a child died following enrolment by parental assent, was understood and supported by most staff. They commented that it would ‘not be good’ or be ‘unethical’ to go back, given the sensitivity of the situation. Parents are typically crying, and sometimes collapsing. However, one staff member thought it was a study requirement to retrospectively obtain full consent even in the event of a death. Several felt that although it would be ‘harsh because someone has just lost their child and they are emotionally upset and all that’, it would have been better to obtain consent retrospectively to protect staff legally.

Parents’ Recall and Perceptions of the Informed Consent Process

As might be expected from staff comments and the medical condition of many children, parents’ descriptions of the admission process and information given at that stage focused on their concern for the child’s health and for their desire for treatment to proceed as fast as possible. Many parents said they ‘cannot remember’ or ‘have forgotten’ what they were told, or that they were ‘not listening to anything’. As one mother described in Soroti:

You know, you can also forget because the things [they told me] were too many and you know being only one head my heart was shaken about how the child was…that’s why [my head] didn’t grab many things (Soroti/FEAST mother/ST 010).

Others had some recollection, sometimes quite detailed, of the consent process and of the content of the discussion, but even these relatively detailed descriptions illustrate some lack of understanding or recall of the relevant trial details, and a hope or belief that inclusion in the trial is positive for the child. Two examples:

It’s a person’s freewill. If you agree to join that group, something like that, that’s when your child will be put some water but if you refuse, your child will not. That’s why she asked me before they put the water in the child and asked me whether I agree or not but I considered my child’s condition and said it’s alright. But the water is really helpful to the child. (Kilifi/Parent/KLF 011; authors’ emphasis).

They said that they are working with Makerere University and they have come to bring a study that involves treating people using fluids or something like that. They told me that it’s not only here, it is also being done in other places and countries including even some countries in Africa and others outside Africa. They are trying to treat children who are very ill using fluids. They also said that the way they have seen in some countries, it seems it is good so they also want to try it in Uganda to check if it is good so that they can see whether to continue that kind of treatment. Then they asked me that do you accept to be with us in this study? That they would treat the child and at the same time studying if I agreed. So I said that I agree, then they started treating the child from that day up to today, the child is still in their hands (Soroti/FEAST Father/ST 011; authors’ emphasis).

Many parents appreciated having been given some information before treatment began, but some felt – sometimes quite strongly - that it was pointless or even an additional worry to be given information and especially being asked ‘opinions’ (i.e. consent) at the stage:

Understanding, [is not something that can happen] until somebody sees her child is fine or recovered, but if you came to me and announce or talk, shouting to me explaining to me about KEMRI when my child is ailing… I won’t listen to you, it’s like you will be talking to the wind and the words will pass with the blowing wind. Because to me I will be looking on the condition of...
my child; not listening to you (Kilifi/Parent/KLF 016; authors' emphasis).

What was not appropriate or what didn’t please me was that of being consulted first … I felt bad because you have come all the way from home because your child is not feeling well, you have brought the child and instead of them taking an urgent step of treating the child they start asking for your advice…. If it were not my decision I wouldn’t have brought the child to this place… (Kilifi/Parent/KLF007; author's emphasis).

Another mother’s comment suggested that the way that consent was administered may not always have been ideal:

I was seated but my child was on a bed somewhere aside… she was even explaining while I had stood up to look at my child. In the end she [the nurse] asked them [the other nurses] to block me from seeing my child [so I would listen]. I cannot complain because they were in a hurry so as for the child to be put [on] the [infusion of] water (Kilifi/Parent/KLF 011).

In Kilifi, some of those who refused suggested that the consent signature indicated a handing over of the child; an absolution of blame on all sides ‘like if anything happens I don’t want us to blame each other’ which was felt to be deeply uncomfortable given the severity of the child’s illness:

You are told it is your decision. That is what is making people refuse because instead of just treating the child so that he/she is cured … It’s like you are saying in case there is anything that happens, I don’t want us to blame each other. Because you will have signed and you won’t have anything to say because you have signed yourself. So that is why people are refusing (Kilifi/Parent/KLF007).

The overwhelming recommendation from parents was for the treatment to come first and the talking and explaining later:

When a child arrives there, let him/her be treated first and then later let [the parents] be asked the questions. I even told the nurses that but they said if you have not yet decided ‘yes’ or ‘no’, we can’t start giving the child water. Now, because I want the child to recover I have to say ‘yes’ so that they can start the water (Kilifi/Parent/KLF 013).

Factors Influencing Parental Decision-making

Many of the above comments, including from staff, illustrate the difficulty of differentiating a trial related treatment intervention from standard of care. Looking across all parents’ responses to questions during our interviews, only 7/39 (18%) appeared to recall the nature of the research they were involved in, 23/39 (59%) recollected some elements of the research, and 9 (23%) simply described their whole experience as clinical care (Table 6). Those with good or some recall described a ‘project’, voluntary participation, and non-routine ‘water’ treatment. For some, simply being asked (i.e. consent) triggered their knowledge that they were in a research project.

Clearly difficult for parents and staff was explaining and understanding the concept of a trial and ‘equipoise’, leading to many parents suggesting that a decision, and particularly saying ‘no’, did not make any sense:

If you refuse what will you do in that condition and I have followed you, you cannot refuse. If I were to refuse, I couldn’t have come with him to the hospital (pause) we are grateful. (Kilifi/Parent/KLF 011; authors’ emphasis).

The above perception may have been contributed to by many of the trial staff apparently not being in equipoise at the time of this consent sub-study, with many believing that the intervention arms would prove to be life saving. As one staff member reported:

we have come to appreciate that at least that rapid infusion of fluids within the first one hour for very sick children really has some benefits so we are even trying to do it informally not only for the FEAST children but for some other children… it has helped us at least come to that conclusion even before the study has concluded (Soroti/Staff/ST009).

Others were concerned that refusal might lead to poorer quality of care, with one parent in Soroti mentioning you would have to ‘go to the other side where you have to buy things’. This might relate to the FEAST patients being relatively distinguishable from others in the ward not participating in the trial in Soroti due to their physical location and also because enrolled children did not have to buy prescribed medicines or infusion lines as often happens for paediatric patients (see Table 4). This difference contributed to trial participants being perceived by parents as getting much better quality of care.

Once you are in that room [study room] you are given everything even the cannula, quinine, the drugs…All you do is to just look and appreciate that the child is being treated. The only expenditure is on what you have to eat and for the child because you see that even life is getting better … Even the nurses are good and the help offered is okay (Soroti/Non-FEAST mother/ST 005).

can wish in your heart that if only you were also the one being treated like that, maybe it would be better (Soroti/Non-FEAST Mother/ST 001).

Certainly, in both settings, participants' parents greatly appreciated the close monitoring and quick attention given to their children while at the ward, and regularly discussed being impressed and pleased by the concern and 'tender care' shown to children by the nurses and doctors.

Parents' relatively low exposure to science and research was often mentioned by staff as contributing to parents' inability to differentiate between research and standard care. In Kilifi, previous information about or personal experience with research studies in the wards or in the community sometimes led to parents automatically refusing the trial, either because they were aware that research participation is voluntary and had no interest in participating, or through a general concern about the institution’s research. The latter was sometimes based on rumours that have been extensively described in Kilifi and elsewhere [18,20], including misperceptions that blood samples are mixed and sold, or that staff are ‘devil-worshippers’. In other cases, past experience or information about KEMRI was much more positive, and appeared to lead to an automatic yes, regardless of understanding of study details:

I told him that I know KEMRI; one of my grandchildren is in a KEMRI malaria vaccine study so I know this organisation. When he
Differences in Consent Types by Site, and Views of the
through raising concerns and doubts at a time when parents are
primarily with parents - was that being asked to make choices and
allowing another opportunity for parents to withdraw, and
allowing other relatives to be involved in the consent process.
allowing a two stage process supporting better understanding,
treatment. Other benefits were described as the formal introduc-
tion of a two stage process supporting better understanding,
relationship between the two key elements of consent: parents are seriously anxious and vulnerable; and staff
are stressed by balancing the urgent need to proceed with
treatment with a concern about being later blamed by parents for
encouraging them to join a trial without meaningful initial
consultation. This latter point is important given staff recognition
of the potentially pivotal role they play in handling a high-risk
group of children.

Discussion

There is widespread agreement on the need for emergency
decisions in paediatric research, arguably particularly in low-income settings
such as sub-Saharan Africa where a disproportionate burden of
child mortality occurs within hospitals, often within hours of
admission. An important challenge with regards to such trials is
developing an appropriate consent process. The interviews we
held with those most closely involved with the FEAST trial reveal
the significant challenges faced in meeting all of the key elements
of consent: parents are seriously anxious and vulnerable; and staff
are stressed by balancing the urgent need to proceed with
treatment with a concern about being later blamed by parents for
encouraging them to join a trial without meaningful initial
consultation. This latter point is important given staff recognition
of the potentially pivotal role they play in handling a high-risk
group of children.

Table 6. Parents’ recall on discharge that their children were in a study.

| Levels of Understanding                  | Kilifi (n = 19) | Soroti (n = 20) | Total (n = 39) |
|-----------------------------------------|----------------|----------------|---------------|
| Clear understanding                     | 3              | 4              | 7             |
| Some elements of trial understood       | 13             | 10             | 23            |
| No apparent distinction from clinical care | 3              | 6              | 9             |

Discussion

Within a generally positive view of the consent process, particularly among staff members, there were also some serious
concerns raised. A major issue - revealed through discussions
primarily with parents - was that being asked to make choices and
listen to information on admission potentially causes harm,
through raising concerns and doubts at a time when parents are
unable to listen, ask, understand, or challenge those they are
seeking help from. Relatedly, is whether voluntary decisions can
ever really be made in this emergency context.

Alternatives to the FEAST Trial Approach to Consent and Areas Needing Further Deliberation and Resolution

The main suggestion or recommendation from parents was that
researchers should ‘just get on with treating their child’, and worry
about consent later. This suggestion from parents in our settings
echoes views of parents in UK gathered through a postal
questionnaire survey aimed at informing a proposed double blind
RCT [13]. However, some aspects of our data suggest caution in
retrospective consent for all (Table 1):

- From a moral perspective, parents have a right to make a
  choice on their own terms [1], because the expert does not
  know everything and cannot know what is best for each person
  in a medical trial. Some parents did refuse, particularly in
  Kilifi, suggesting that prior assent or consent does give some
  people a choice, and interviews with refusals did not suggest
  that parents regretted this refusal;
- Some parents appreciated being given some information and
  an opportunity to opt out, despite recognising the difficulties in
  understanding;
- Most staff felt that it would be inappropriate not to give parents
  any choice prior to starting the study, for both moral and –
  possibly more strongly - legal reasons;
- Parents who recommended mandatory retrospective consent
did not always appear to have a full understanding that their
child had been involved in a trial. Parents’ recommendations
may have differed significantly if they had understood their
child had been involved in a trial, and the implications of
this, more fully.
- Over time, there is a possibility that in a context of some
  concerns about, and distrust in research, an awareness that
  children could be enrolled without any prior information or
  option to opt out, could undermine public trust in health
  services and in researchers.
- We did not interview a key group of parents; those whose
  children had died, whose views - if based on an understanding
  of the trial and its implications – may have differed
  significantly.

An alternative to retrospective consent would be to implement
deferred consent with a prior assent for all. Parents’ descriptions suggest
that regardless of the severity of the illness in clinical terms, a child
entering into an HDU with an acute illness leads to such anxiety
that all parents effectively meet the criteria for deferred consent
with prior assent. If the assent process information included a clear
option for full consent at the point of admission if parents wanted
it, the parent would then have greater control themselves on the
amount of information they received on admission, rather than
leaving it to staff to assess suitability based on a predefined criteria,
or staff making the subjective decision about levels of ‘parental distress’.

A challenge with the latter is staff members’ preference particularly in Kilifi for a one-step full consent process in advance in order to comply with all the legal requirements of research inclusion in one go. However full consent at enrolment is unlikely to meet the moral commitment to individual choice even if fulfilling the legal commitment [21]. This preference may also have in part been related to some lack of clarity among staff that the national ethics committee which approved the trial has been accredited by the Pharmacy and Poison’s Board (PPB) and the National Council for Science & Technology (NCST); and that the PPB and NCST have in turn been delegated the authority nationally to regulate clinical trials. The two-step prior assent followed by full later consent process for all, or possibly even a more continuous consent process [22], with an option for parents to choose full prior consent, potentially allows both the moral and legal approaches to consent to be met. An important problem is that the confusions, anxieties and delays introduced by parents being presented with and facing a choice on admission are not avoided.

Given the challenges with each option raised above, future similar studies would potentially benefit from more prior community consultation on the above options, and on further more specific issues raised by this study, as discussed below:

**What to do in the absence of the father, or both parents.** Consenting non-parents has been practised by others, where circumstances for deferred consent have included ‘physical absence of the patient’s relative [in such a circumstance]... as soon as relatives arrive, this circumstance is no longer valid, and hence consent should immediately be sought’ [Jansen, p 997]. We found that ‘buying time’ does not necessarily build confidence in a moral commitment to the goals of consent processes, as opposed to a determination to achieve the study sample sizes.

Literature from this part of the world and our data suggest that there might be serious harms from proceeding with a trial in the absence of a parent or father’s approval, including domestic violence, mothers or grandparents being blamed for a child’s death, and households being split [18]. In situations with strongly inequitable power relations such as vulnerable clinical contexts [23], mothers also sometimes request to wait for their husbands as a way of ‘silently refusing’, as a way of exercising their own agency [24]. Although fears and concerns leading to silent refusals might be related more to a community or an individual’s lack of trust in research or in the research staff, rather than to issues specific to a trial, an ability to refuse is a right, even if it is based on apparently ‘irrational’ argument [1].

The challenge with accepting all deferrals of research decisions to fathers in settings like Soroti and especially Kilifi is that the majority of mothers bring their children to hospital without their husbands. It may also be that many fathers would regret their wives not having agreed to studies when they are later informed, particularly given that most trials have a positive impact on all participants – the trial effect – regardless of which arm they are in; a positive impact which was noted in the FEAST trial, and also [25] perceived by parents of FEAST trial participants, particularly in Soroti. Another challenge is the cost and size of studies and the potential to introduce bias, if all mothers wanting to wait for husbands is strongly adhered to. At this stage, without further information, it is difficult to justify not allowing mothers to wait for their husbands or for relatives to wait for parents; an approach which appeared to contribute to relatively high refusal rates in Kilifi. To argue otherwise would be to weigh cost against very real risks to mothers, and their ability to exercise choice; i.e. the moral goal of consent [26].

**What does consent mean in the deferred consent process?.** Beyond the issues raised above about who can consent, Kilifi staff in particular raised a concern about whether an affirmative ‘yes’ was needed from those providing the assent. With most parents overwhelmed and distressed by their child’s condition on arrival, ascertaining a positive response from some parents was difficult. Some staff felt that it was essential to have a clear go ahead while others felt that this should not be mandatory because it introduces additional unnecessary pressures and delays. One potential option moving forwards would be to consider the assent process as an opt out opportunity, where those who are generally opposed to any research can refuse, either openly or through the silent approaches noted above, regardless of their reasons. Here there would an acceptance of some loss of voluntariness in order to minimise the risks and distress associated with taking time to give a definitive response. A related challenge is the precise assent information that is given, and in particular how to distinguish between usual clinical care and interventions or procedures specific to clinical research in a way that is brief but clear. Clinical research, clinical care and quality improvement overlap so much that decisions are potentially rendered meaningless.

**Should parents be consented retrospectively after the death of their child?.** Current recommendations require that the relatives or guardians of a research subject entered into a clinical investigation with waived consent be informed of their participation even after death [21CFR50.24]. The FEAST trial did not do this, for similar reasons to others. For example Jansen et al (2007) noted:

‘Confronting relatives again with the event that their loved one died on the ICU can be seen as harm or burden... If we can say that confronting bereaved relatives represents additional burden, which we have the duty [as providers] to relieve or prevent, it seems morally correct to adopt policies that prevent seeking deferred consent from proxy’s after their relatives’ death’ (p997).

Shilling and Young (2009) also showed that parents feared making a ‘wrong decision’ and living with the knowledge that the ‘wrong decision’ led to a poor outcome. In retrospect, this might have particularly applied to parents of children in the FEAST trial, given the unexpected negative findings, although as noted above there is a strong suggestion that there was a positive trial effect on all participating children. Our interviews with staff members suggest that choosing not to proceed with the full consent process after the death of a child was appropriate, humane and appreciated. However, we did not interview parents of children who had died, and there were some staff members who were concerned that parents should be informed primarily for legal protection reasons. Although staff could potentially be reassured about the legal issues, a challenge with not fully informing parents is the possibility in the longer term of parents perceiving that full information had been concealed from them, with potentially negative implications for trust and future research [13].

**Do parents have a choice?.** A particularly fundamental concern with meeting the moral commitment of consent is that of parents being so desperate or vulnerable that they feel ‘they have no choice’. Where this choice is based on an obvious disparity between the standard of care or costs for participants and non-participants, as was apparently more the case in Soroti, this raises potential concerns about undue inducement [27], and suggests the
Activities to Support Strengthened Consent Processes

Good training and consent support processes are clearly essential for staff involved in emergency trials, with an important set of communications skills required including being able to read and respond to the variability among parents (in terms of their mood, understanding and information needs at a given time), and being able to recognise silent agreements or refusals. The FEAST trial training and supportive supervision processes, including for consent, were greatly appreciated by staff, and are essential in all research settings given that frontline staff are constantly making ethically important decisions [14,30]. Our data suggests that supportive supervision needs to be constant, and to be seeking out and responding continuously to challenges and areas lacking clarity as they arise. This support should continue after a trial is ended, possibly especially where there are unexpected findings: however carefully, equipoise has been explained in initial protocols and trainings, frontline staff may develop their own expectations and interpretations. Our data also suggest that consent training should include discussion and debate on ethical and moral approaches to consent, including: 1) national and international review processes, including why and how alternatives to full prior consent are approved, and how staff are legally protected; and 2) how best to ensure that on a day-to-day basis, the legal elements and requirements of a trial do not outweigh the moral [31].

Conclusion

The overall approach of using a deferred consent process with a prior assent was generally supported, particularly by trial clinicians and nurses. Prior assent was seen as protecting the interests of both patients and researchers, including through minimising delays in starting treatment. The potential challenges were voluntariness being undermined through inadequate assent information being poorly understood, and any information giving on admission acting as a form of harm or disadvantage through causing real or perceived delays. Further challenges raised included what to do in the absence of a father, and what it means and what to do when mothers do not give a clear agreement or refusal. While these challenges are faced in all studies, they are magnified by the urgency of the situation, and the need to make rapid decisions.

Possible ways forward for consent for paediatric emergency research depend on the level of risk of a study, and on the context. For a minimal risk study a consent waiver or retrospective consent may be considered appropriate. For a non-minimal risk study like FEAST, one possible option is prior assent for all parents, with an option for full prior consent given as part of the assent information. This approach would consider assent essentially as an opt-out mechanism, whereby some loss of voluntariness is accepted in order to minimise the risks and distress associated with taking time to give a definitive response.

Regardless of the approach adopted, the importance of strong communication skills and support for all frontline staff, and their understanding of the moral bases for consent, and of the science and ethics review process and of the legal protections they have, is clear. Nevertheless, concrete decisions on ways forwards requires further discussion and reflection, including through consultation with staff members and community representatives, including men, using a deliberative approach.

Acknowledgments

We thank all the participating sites, site staff and interviewees, and are grateful to those who assisted us with the parent interviews (Norah Kyazike, Anderson Charo, Gladys Sanga, Jane Kahindi and Isaac Charo) and to Elizabeth Russell for her support with the quantitative consent data. We also appreciate support and inputs into the proposal from Dr Sam Akech and Trudie Lang, and valuable comments on the paper from Dr Vicki Marsh and Professor Mike Parker. This article is published with the permission of the director, KEMRI.

Author Contributions

Provided critical comments on the manuscript: MB LA POO CE SK. Approved the final version of the manuscript: SM MN MB LA POO CE SK KM. Conceived and designed the experiments: SM MB LA POO CE SK KM. Analyzed the data: SM MN. Contributed reagents/materials/analysis tools: SM MN. Wrote the paper: SM MN KM.

References

1. Brierley J, Larcher V (2011) Emergency research in children: options for ethical recruitment. J Med Ethics 37: 429–432.
2. Jansen TC, Kompanje EJ, Druml C, Menon DK, Wiedermann CJ, et al. (2007) Deferred consent in emergency intensive care research: what if the patient dies early? Use the data or not? Intensive Care Med 33: 894–900.
3. Maitland K, Molyneux S, Boga M, Kiguli S, Lang T (2011) Use of deferred consent for severely ill children in a multi-centre phase III trial. Trials 12: 90.
4. FDA, U.S. Food and Drug Administration (April 1, 2012) Title 21 CFR 50.24. Informed Consent.
5. Clinical Trials Regulations (2006) The Medicines for Human Use (Clinical Trials) Amendment (No.2) Regulations 2006.
6. Largent EA, Wendler D, Emanuel E, Miller FG (2010) Is emergency research without initial consent justified?: the consent substitute model. Arch Intern Med 170: 668–674.
7. Manning DJ (1999) Presumed consent in emergency neonatal research. J Med Ethics 26: 249–253.
8. Emanuel EJ, Wendler D, Grady C (2000) What makes clinical research ethical? JAMA 283: 2701–2711.
9. Emanuel EJ, Wendler D, Killen J, Grady C (2004) What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infect Dis 189: 930–937.
10. Luce JM (2003) Is the concept of informed consent applicable to clinical research involving critically ill patients? Crit Care Med 31: S153–160.
11. Maitland K, Kiguli S, Opoka RO, Engesa C, Olupot-Olupot P, et al. (2011) Mortality after fluid boluses in African children with severe infection. N Engl J Med 364: 2483–2495.
12. Jansen TC, Bakker J, Kompanje EJ (2010) Inability to obtain deferred consent due to early death in emergency research: effect on validity of clinical trial results. Intensive Care Med 36: 1962–1965.
13. Gamble C, Nadel S, Snape D, McKay A, Hickey H, et al. (2012) What Parents of Children Who Have Received Emergency Care Think about Deferring Consent in Randomised Trials of Emergency Treatments: Postal Survey. PLoS ONE 7: e35862.
14. Boga M, Davies A, Kamunya D, Kinyanjui SM, Kwaya E, et al. (2011) Strengthening the informed consent process in international health research through community engagement. The KEMRI-Wellcome Trust Research Programme Experience. PLoS Med 8: e1001089.
15. Brierley J, Carsillo JA, Choong K, Cornell T, Decaen A, et al. (2009) Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 37: 666–688.
16. World Health Organization (2005) Emergency Triage Assessment and Treatment (ETAT): Manual for Participants.
17. Green J,Thorogood N (2009) Qualitative Methods for Health Research. London: SAGE Publications Ltd.
18. Molyneux CS, Peshu N, Marsh K (2004) Understanding of informed consent in a low-income setting: three case studies from the Kenyan Coast. Social Science and Medicine 59: 2547–2559.

19. Molyneux CS, Peshu N, Marsh K (2005) Trust and informed consent: insights from community members on the Kenyan Coast. Social Science and Medicine 61: 1463–1473.

20. Molyneux CS, Wassenaar D, Peshu N, K M (2005) ‘Even if they ask you to stand by a tree all day, you will have to do it’: community voices on the notion and practice of informed consent. Social Science and Medicine 61: 445–454.

21. Lairumbi GM, Parker M, Fitzpatrick R, English MC (2012) Forms of benefit sharing in global health research undertaken in resource poor settings: A qualitative study of Stakeholders’ views in Kenya. Philos Ethics Humanit Med 7: 7.

22. Allmark P, Mason S (2006) Improving the quality of consent to randomised controlled trials by using continuous consent and clinician training in the consent process. Journal of Medical Ethics 32: 439–443.

23. Molyneux CS, Murira G, Masha J, Snow RW (2002) Intra-household relations and treatment decision-making for childhood illness: a Kenyan case study. J Biosoc Sci 34: 109–131.

24. Kamuya D, Theobald S, Munywoki P, Koech D, Geissler P, et al. (2013) Evolving friendships and shifting ethical dilemmas: fieldworkers’ experiences in a short term community based intensive household study. Developing World Bioethics 13(1): In Press.

25. Myburgh JA (2011) Fluid resuscitation in acute illness–time to reappraise the basics. N Engl J Med 364: 2543–2544.

26. Lindegger G, Richter LM (2000) HIV vaccine trials: critical issues in informed consent. S Afr J Sci 96: 313–317.

27. Emanuel EJ, Currie NE, Herman A (2005) Undue inducement in clinical research in developing countries: is it a worry? Lancet 366: 336–340.

28. Lairumbi GM, Parker M, Fitzpatrick R, English MC (2012) Forms of benefit sharing in global health research undertaken in resource poor settings: a qualitative study of stakeholders’ views in Kenya. Philos Ethics Humanit Med 7: 7.

29. Molyneux S, Mulupi S, Mbaabu L, Marsh V (2012) Benefits and payments for research participants: Experiences and views from a research centre on the Kenyan coast. BMC Med Ethics 13: 13.

30. Van Loon K, Lindegger G (2009) Informed consent in clinical trials: Perceptions and experiences of a sample of South African researchers. 2009 14.

31. Marsh VM, Kamuya DK, Parker MJ, Molyneux CS (2011) Working with Concepts: The Role of Community in International Collaborative Biomedical Research. Public Health Ethics 4: 26–39.

32. Pariyo GW, Ekirapa-Kiracho E, Oka O, Rahman MH, Peterson S, et al. (2009) Changes in utilization of health services among poor and rural residents in Uganda: are reforms benefiting the poor? Int J Equity Health 8: 39.

33. Chuma J, Musimbi J, Okungu V, Goodman C, Molyneux C (2009) Reducing user fees for primary health care in Kenya: Policy on paper or policy in practice? Int J Equity Health 8: 15.